DISCOUNT OPTIONSSCHEIN - MODERNA | Market Closed - Deutsche Boerse AG 01:50:23 2024-06-07 pm EDT | ||
| 1.4 EUR | -4.11% |
|
| Current month | +12.00% | ||
| 1 month | +59.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 1.4 | -4.11% |
| 24-06-06 | 1.46 | +2.82% |
| 24-06-05 | 1.42 | +10.08% |
| 24-06-04 | 1.29 | -1.53% |
| 24-06-03 | 1.31 | +4.80% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 01:50 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU9HA3 |
| ISIN | DE000VU9HA35 |
| Date issued | 2023-07-05 |
| Strike | 125 $ |
| Maturity | 2024-12-20 (194 Days) |
| Parity | 10 : 1 |
| Emission price | 0.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.61 € |
|---|---|
| Lowest since issue | 0.27 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151
USD
Average target price
143.9
USD
Spread / Average Target
-4.68%
- Stock Market
- Certificates
- Certificat
